Association between gene expression profile, proliferation and metastasis in uveal melanoma.
OBJECTIVE
Uveal melanomas cluster into two molecular groups based on their gene expression profile. Tumors with the class 1 signature rarely metastasize, whereas those with the class 2 signature have a very high rate of metastasis. However, the biological basis for this metastatic propensity of class 2 tumors remains unclear. Towards such an explanation, this study was conducted to determine whether class 2 tumors have a higher proliferative rate than class 1 tumors.


METHODS
The study included 28 primary uveal melanomas with extensive clinical, pathologic, and genetic annotation, including age, gender, ciliary body involvement, tumor basal diameter, thickness, cell type, gene expression profile, status of chromosomes 3 and 8p, aneuploidy, and clinical outcome. Immunopositivity for Ki-67 was determined by counting all positive nuclei in representative whole tumor sections.


RESULTS
Ki-67 positivity was significantly associated with class 2 gene expression profile, loss of chromosome 3 and increased aneuploidy (P = 0.04, P = 0.004, and P = 0.03, respectively). Ki-67 positivity showed a borderline significant association with epithelioid cell type (P = 0.07). Receiver operating characteristic (ROC) analysis of Ki-67 positivity, using the class 2 signature as an endpoint, identified a Ki-67 score of approximately 20 cells per high power field as the optimal cut-off point between low and high risk for metastasis (log rank test, P = 0.01).


CONCLUSIONS
On average, class 2 uveal melanomas have a higher proliferative rate than class 1 tumors. Further work is needed to determine whether loss of chromosome 3, increased aneuploidy, or other factors may be responsible for the increased proliferation.
Onken
Michael D
MD
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Worley
Lori A
LA
Harbour
J William
JW
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000782:Aneuploidy; D049109:Cell Proliferation; D002893:Chromosomes, Human, Pair 3 / Q000235:genetics; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen / Q000378:metabolism; D008113:Liver Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000556:secondary; D019656:Loss of Heterozygosity / Q000235:genetics; D008297:Male; D008545:Melanoma / Q000235:genetics* / Q000378:metabolism / Q000556:secondary; D008875:Middle Aged; D012333:RNA, Messenger; D014604:Uveal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology
D019394:Ki-67 Antigen; D012333:RNA, Messenger
Ophthalmology. 2001 Feb;108(2):367-71
11158814
Curr Eye Res. 1991 May;10(5):479-84
1889233
Melanoma Res. 2008 Jun;18(3):191-200
18477893
Cancer Res. 2006 May 1;66(9):4602-9
16651410
Clin Cancer Res. 2007 Mar 1;13(5):1466-71
17332290
Clin Cancer Res. 2008 Jan 1;14(1):115-22
18172260
Clin Cancer Res. 2008 Jun 15;14(12):3737-45
18559591
Am J Ophthalmol. 2005 Oct;140(4):748-9
16226537
Nat Rev Cancer. 2009 Mar;9(3):153-66
19238148
Eur J Cancer. 1996 Feb;32A(2):357-62
8664054
Curr Eye Res. 2006 Jan;31(1):57-67
16421020
Cancer Res. 2004 Oct 15;64(20):7205-9
15492234
Int J Cancer. 1983 Jan 15;31(1):13-20
6339421
Curr Eye Res. 2002 Feb;24(2):105-8
12187481
Ophthalmology. 1990 Oct;97(10):1275-80
2243677